RxDoctor Payments DataLook up a doctor →

Elisha Clark, NP

Family · Cambridge, OHNPI 1750664108

Payments from drug & device makers

$31,513in general payments, 2019–2025

Across 419 payments — averaging $75.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$14K
  • Novo Nordisk$9K
  • AbbVie$1K
  • AstraZeneca$893
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$657
  • Exact Sciences$553
  • plus $5K from 40 others

What the payments were for

  • Consulting fees$2,7089%
  • Speaking & faculty fees$18,33358%
  • Travel & lodging$7222%
  • Food & beverage$9,73331%
  • Education$170%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,513 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$45,402
Medicare patients
115
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$141,999
EliquisApixaban48$57,807
MounjaroTirzepatide44$51,414
Nurtec OdtRimegepant Sulfate20$27,043
XareltoRivaroxaban20$24,073
TrulicityDulaglutide16$15,898
Repatha SureclickEvolocumab23$14,177
LinzessLinaclotide17$11,731
Albuterol Sulfate HfaAlbuterol Sulfate280$7,957
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl303$7,141
Glucagon Emergency KitGlucagon13$6,119
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,494
Gabapentin255$3,383
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$3,346
Ondansetron OdtOndansetron148$2,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$9,249$141,999138 claims
PfizerEliquis, Nurtec Odt$384$84,85068 claims
Lilly USA, LLCMounjaro, Trulicity$385$67,31160 claims
Johnson & JohnsonXarelto$75$24,07320 claims
AbbVieLinzess$1,421$11,73117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Cambridge

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →